SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Wedel Hans) "

Sökning: WFRF:(Wedel Hans)

  • Resultat 1-10 av 88
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Angerås, Oskar, 1976, et al. (författare)
  • Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients with ST-Segment-Elevation Myocardial Infarction: A Report From the Swedish Coronary Angiography and Angioplasty Registry
  • 2018
  • Ingår i: Journal of the American Heart Association. - : John Wiley & Sons. - 2047-9980. ; 7:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background-Thrombus aspiration is still being used in a substantial number of patients despite 2 large randomized clinical trials showing no favorable effect of routine thrombus aspiration during primary percutaneous coronary intervention in patients with STsegment- elevation myocardial infarction. The aim of this observational study was to evaluate the impact of thrombus aspiration on mortality, stent thrombosis, and stroke using all available data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Methods and Results--We identified 42 829 consecutive patients registered in SCAAR between January 2005 and September 2014 who underwent percutaneous coronary intervention for ST-segment-elevation myocardial infarction. Thrombus aspiration was used in 25% of the procedures. We used instrumental variable analysis with administrative healthcare region as the treatmentpreference instrumental variable to evaluate the effect of thrombus aspiration on mortality, stent thrombosis, and stroke. Thrombus aspiration was not associated with mortality at 30 days (risk reduction: -1.2; 95% confidence interval [CI] , -5.4 to 3.0; P=0.57) and 1 year (risk reduction: -2.4; 95% CI, -7.6 to 3.0; P=0.37). Thrombus aspiration was associated with a lower risk of stent thrombosis both at 30 days (risk reduction: -2.7; 95% CI, -4.1 to -1.4; P < 0.001) and 1 year (risk reduction: -3.5; 95% CI, -5.3 to -1.7; P < 0.001). In-hospital stroke and neurologic complications did not differ between groups (risk reduction: 0.1; 95% CI, -0.8 to 1.1; P=0.76). Conclusions--Mortality was not different between the groups. Thrombus aspiration was associated with decreased risk of stent thrombosis. Our study provides important evidence for the external validity of previous randomized studies regarding mortality.
  •  
2.
  • Carlsson, Lena M S, 1957, et al. (författare)
  • Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects.
  • 2012
  • Ingår i: The New England journal of medicine. - : Massachusetts Medical Society. - 1533-4406 .- 0028-4793. ; 367:8, s. 695-704
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • Weight loss protects against type 2 diabetes but is hard to maintain with behavioral modification alone. In an analysis of data from a nonrandomized, prospective, controlled study, we examined the effects of bariatric surgery on the prevention of type 2 diabetes.
  •  
3.
  •  
4.
  •  
5.
  • Kjeldsen, Sverre E, et al. (författare)
  • Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy : the losartan inventervention for endpoint reduction in hypertension study
  • 2009
  • Ingår i: Blood Pressure. - 0803-7051 .- 1651-1999. ; 18:6, s. 348-361
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective. We assessed readily available patient characteristics, including albuminuria (not included in traditional cardiovascular risk scores), as predictors of cardiovascular events in hypertension with left ventricular hypertrophy (LVH) and developed risk algorithms/scores for outcomes. Methods. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study compared effects of losartan-based versus atenolol-based therapy on cardiovascular events in 9193 patients with hypertension and LVH. Univariate and multivariate analyses identified baseline variables with significant impact on development of the primary composite endpoint (cardiovascular death, stroke and myocardial infarction) and its components. Multivariate analysis used a Cox regression model with stepwise selection process. Risk scores were developed from coefficients of risk factors from the multivariate analysis, validated internally using naïve and jack-knife procedures, checked for discrimination and calibration, and compared with Framingham coronary heart disease and other risk scores. Results. LIFE risk scores showed increasing endpoint rates with increasing quintile (first to fifth quintile, composite endpoint 2.8–26.7%, cardiovascular death 0.5–14.4%, stroke 1.2–11.3%, myocardial infarction 1.4–8.1%) and were confirmed with a jack-knife approach that adjusts for potentially optimistic bias. The Framingham coronary heart disease and other risk scores overestimated risk in lower risk patients and underestimated risk in higher risk patients, except for myocardial infarction. Conclusion. A number of patient characteristics predicted cardiovascular events in patients with hypertension and LVH. Risk scores developed from these patient characteristics, including albuminuria, strongly predicted outcomes and may improve risk assessment of patients with hypertension and LVH and planning of clinical trials.
  •  
6.
  •  
7.
  •  
8.
  • Olsen, Michael Hecht, et al. (författare)
  • Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy : the losartan intervention for endpoint reduction in hypertension (LIFE) study
  • 2009
  • Ingår i: Journal of Hypertension. - 0263-6352 .- 1473-5598. ; 27:3, s. 567-574
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: Beta-blockers and angiotensin II receptor blockers have different effects on lipids. Methods: We examined lipid levels in the Losartan Intervention For Endpoint reduction in hypertension study and their impact on the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke. We measured total and high-density lipoprotein cholesterol at baseline and annually during 4.8 years of losartan-based compared with atenolol-based treatment in 8611 patients with hypertension and left ventricular hypertrophy. Results: Patients randomized to losartan-based or atenolol-based treatment had similar baseline total (6.04 ± 1.12 vs. 6.05 ± 1.13 mmol/l, NS) and high-density lipoprotein (HDL) cholesterol (1.50 ± 0.44 vs. 1.49 ± 0.44 mmol/l, NS). Total cholesterol decreased significantly but equally (-0.37 ± 1.05 vs. -0.34 ± 1.09 mmol/l, NS), whereas HDL cholesterol decreased less during the first 2 years in patients randomized to losartan compared with atenolol (-0.13 ± 0.24 vs. -0.19 ± 0.25 mmol/l) and remained higher each year (1.38, 1.37, 1.42, 1.47, and 1.48 mmol/l vs. 1.32, 1.30, 1.36, 1.40, and 1.42 mmol/l, all P < 0.001) independent of hydrochlorothiazide or statin treatment. In Cox regression analysis, baseline total cholesterol [hazard ratio (HR) = 1.08 (1.02–1.14) per mmol/l, P < 0.01], HDL cholesterol [HR = 0.56 (0.48–0.66) per mmol/l, P < 0.001], and treatment allocation [HR = 0.86 (0.76–0.98), P < 0.05] predicted composite endpoint independently. Using time-varying analyses, the predictive strength of HDL cholesterol was increased [HR = 0.36 (0.30–0.44) per mmol/l, P < 0.001], whereas that of total cholesterol [HR = 1.03 (0.97–1.09) per mmol/l, NS] and treatment allocation [HR = 0.91 (0.80–1.03), NS] were reduced. Conclusion: Losartan blunted the decrease in HDL cholesterol during antihypertensive treatment in the LIFE study. Higher intreatment HDL cholesterol was associated with fewer composite endpoints and may partly explain the better outcome of losartan-based treatment.
  •  
9.
  •  
10.
  • Ridell, Börje, et al. (författare)
  • Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983-1992.
  • 2000
  • Ingår i: European journal of haematology. - 0902-4441. ; 65:4, s. 267-71
  • Tidskriftsartikel (refereegranskat)abstract
    • An estimation of the incidence of polycythaemia vera (PV), essential thrombocythaemia (ET) and chronic idiopathic myelofibrosis (CIM) in the city of Göteborg, Sweden during the period 1983-1992 was made from a retrospective case analysis of patients registered as chronic myeloproliferative disorders (CMPD) at the Departments of Medicine and the Department of Pathology of the two major hospitals in the city. A total of 125 cases of PV, 56 males and 69 females were identified. The number of cases as well as the age-specific incidence increased with age. The over all annual gender-specific incidence was 2.69 cases per 10(5) male inhabitants and 3.12 cases per 10(5) female inhabitants. The incidence of PV in relation to the European Standard Population was 2.02 cases per 10(5) inhabitants and year. There were 72 cases, 20 males and 52 females, with ET. The age-specific incidence was in all ages higher for females than for males and increased with age. The annual gender-specific incidence was 0.96 per 10(5) male inhabitants and 2.35 per 10(5) female inhabitants. The incidence of ET in relation to the European Standard Population was 1.28 per 10(5) persons and year. There were 20 cases of CIM, 11 males and 9 females. The annual gender-specific incidence of CIM was 0.53/10(5) male inhabitants and 0.41/10(5) female inhabitants. The incidence of CIM in relation to the European Standard Population was 0.31 per 10(5) persons and year. Seven persons, 2 males and 5 females, had a CMPD that could not be included in any of the above-mentioned groups, but were registered as CMPD, unclassified.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 88
Typ av publikation
tidskriftsartikel (86)
rapport (1)
annan publikation (1)
Typ av innehåll
refereegranskat (84)
övrigt vetenskapligt/konstnärligt (4)
Författare/redaktör
Wedel, Hans (85)
Wikstrand, John, 193 ... (12)
Lind, Marcus, 1976 (12)
Rosengren, Annika, 1 ... (11)
Kjekshus, John (9)
Sjöström, Lars (8)
visa fler...
Lindholm, Lars H (8)
Devereux, Richard B. (8)
Nieminen, Markku S. (8)
Kjeldsen, Sverre E. (8)
Ibsen, Hans (7)
Lissner, Lauren, 195 ... (7)
Svärdsudd, Kurt (7)
Bengtsson, Calle, 19 ... (7)
Hjalmarson, Åke, 193 ... (7)
Näslund, Ingmar (7)
Oparil, Suzanne (7)
Fyhrquist, Frej (7)
Lederballe-Pedersen, ... (7)
Lönroth, Hans, 1952 (6)
Carlsson, Lena M S, ... (6)
Jacobson, Peter, 196 ... (6)
Waagstein, Finn, 193 ... (6)
de Faire, Ulf (6)
Carlsson, Björn, 195 ... (6)
Peltonen, Markku, 19 ... (6)
Dahlöf, Björn (6)
Julius, Stevo (6)
Kjekshus, J (5)
McMurray, John J. V. (5)
Lindroos, Anna-Karin ... (5)
Pivodic, A. (5)
van Veldhuisen, Dirk ... (5)
Cleland, J. G. F. (5)
Bouchard, Claude (5)
Dunselman, Peter (5)
Beevers, Gareth (5)
Svensson, Ann-Marie, ... (4)
McMurray, J. J. V. (4)
Gudbjörnsdottir, Sof ... (4)
Björkelund, Cecilia, ... (4)
Karason, Kristjan, 1 ... (4)
Ahlin, Sofie, 1985 (4)
Svensson, Per-Arne, ... (4)
Anveden, Åsa (4)
Cleland, John G. F. (4)
Wilhelmsen, Lars, 19 ... (4)
Dahlgren, Sven (4)
Cabrera-Moksnes, Cla ... (4)
Edelman, Jonathan M (4)
visa färre...
Lärosäte
Göteborgs universitet (67)
Karolinska Institutet (16)
Uppsala universitet (14)
Umeå universitet (12)
Lunds universitet (6)
Örebro universitet (5)
visa fler...
Linköpings universitet (5)
Jönköping University (3)
Högskolan i Skövde (3)
Handelshögskolan i Stockholm (2)
Stockholms universitet (1)
Chalmers tekniska högskola (1)
Högskolan i Borås (1)
RISE (1)
visa färre...
Språk
Engelska (87)
Svenska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (61)
Teknik (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy